SCHEMBL7776292

SCHEMBL7776292

COc1ccccc1-c1nc(N)nc(O)c1Br

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.57
ADORA1 P30542 2/20 0.56
ALDH1A1 P00352 5/20 0.49
HSP90AA1 P07900 2/20 0.48
HSP90AB1 P08238 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
USP2 O75604 1/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 1/20 0.46
HPGD P15428 1/20 0.45
LRRK2 Q5S007 1/20 0.44
KDM4E B2RXH2 3/20 0.43
DHFR P00374 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7776147 0.82 ADORA2A (0.57) ADORA2AADORA1ALDH1A1HSP90AA1HSP90AB1
SCHEMBL7777502 0.82 ADORA2A (0.57) ADORA2AADORA1ALDH1A1HSP90AA1HSP90AB1
SCHEMBL7770058 0.77 ADORA2A (0.54) ADORA2AADORA1ALDH1A1SMN1; SMN2TSHR
SCHEMBL27881848 0.77 ADORA2A (0.57) ADORA2AADORA1ALDH1A1HSP90AA1HSP90AB1
SCHEMBL7774732 0.76 DHFR (0.44) ADORA2AALDH1A1SMN1; SMN2MAPTPOLB
SCHEMBL1679097 0.73 ALDH1A1 (0.51) ADORA2AADORA1ALDH1A1HSP90AA1HSP90AB1
SCHEMBL4408835 0.73 ADORA2A (0.60) ADORA2AADORA1ALDH1A1HSP90AA1HSP90AB1
Bropirimine SCHEMBL4321472 0.73 ADORA2A (0.50) ADORA2AADORA1POLBDHFR
SCHEMBL9131702 0.72 ADORA2A (0.41) ADORA2AADORA1SMN1; SMN2JAK2
SCHEMBL7774476 0.71 ADORA2A (0.58) ADORA2AADORA1MAPTTSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2001505911-A 2001-05-08 JP claimed
EP-0948331-A2 METHOD FOR TREATING MULTIPLE SCLEROSIS PHARMACIA & UPJOHN COMPANY (US) 1999-10-13 EP claimed
WO-1998025596-A2 USE OF A 6-ARYL PYRIMIDINE COMPOUND FOR TREATING MULTIPLE SCLEROSIS PHARMACIA & UPJOHN COMPANY (US) 1998-06-18 WO claimed
US-5434157-A Active against herpes, hepatitis, papovavirus THE UPJOHN COMPANY (US) 1995-07-18 US claimed
EP-0948331-A2 METHOD FOR TREATING MULTIPLE SCLEROSIS PHARMACIA & UPJOHN COMPANY (US) 1999-10-13 EP disclosed
WO-1998025596-A2 USE OF A 6-ARYL PYRIMIDINE COMPOUND FOR TREATING MULTIPLE SCLEROSIS PHARMACIA & UPJOHN COMPANY (US) 1998-06-18 WO disclosed
US-5554617-A Method for treating cancer with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1996-09-10 US disclosed
US-5434157-A Active against herpes, hepatitis, papovavirus THE UPJOHN COMPANY (US) 1995-07-18 US disclosed
US-5002951-A 2-amino-5-halo-4-pyrimidinol for bactericides and antiprotozoa agent THE UPJOHN COMPANY (US) 1991-03-26 US disclosed
US-4665077-A IMMUNOREGULATORY AGENTS THE UPJOHN COMPANY (US) 1987-05-12 US disclosed
US-4619933-A 6-aryl pyrimidines for treating aplastic anemia THE UPJOHN COMPANY (US) 1986-10-28 US disclosed
US-4543248-A Method for immunoregulation with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1985-09-24 US disclosed
US-4507302-A Method for treating arthritis with 6-aryl pyrimidine compounds THE UPJOHN COMPANY (US) 1985-03-26 US disclosed